Principal Investigator
Byron Lam
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20250292
Clinical Trial Summary
A Repeat-Dose, Open-Label, Four Arm Safety and Efficacy Study of Two Doses of VP-001 (75 g and 120 g) Administered Intravitreally in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy and Previously Treated with VP001 in the PLATYPUS Study (Protocol # VP001-101) or WALLABY Study (Protocol # VP001-102) for a Minimum of 8 Weeks
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other